BioCentury | Apr 21, 2014
Politics, Policy & Law

ASCO's honest broker

A new access program and registry developed by the American Society of Clinical Oncology to facilitate use of off-label cancer drugs could serve as a model for independent bodies that could manage early access to...
BioCentury | Nov 22, 2010
Company News

T-Ray Science, BC Cancer Agency deal

...an additional 200,000 five-year warrants exercisable at C$0.18 to the agency (see BioCentury, July 19). T-Ray Science Inc....
BioCentury | Jul 26, 2010
Financial News

T-Ray Science proposes private placement of units

T-Ray Science Inc. (TSX-V:THZ), Vancouver, B.C. Business: Diagnostic Date announced: 7/14/10 Type: Private placement of units To be raised: Up to C$660,000 (US$628,188) Units: 3 million Price: C$0.22 (unit) Shares outstanding prior: 33.1 million Note:...
BioCentury | Jul 19, 2010
Company News

T-Ray Science, BC Cancer Agency deal

...warrant exercisable at $0.25, T-Ray's closing price on July 13, the day the deal closed. T-Ray Science Inc....
BioCentury | Jan 25, 2010
Company News

T-Ray Science management update

T-Ray Science Inc. (TSX-V:THZ), Vancouver, B.C. Business: Diagnostic Hired: Tom Walker as SVP of business development, formerly president and CEO of Rapid Laboratory Microsystems Inc. WIR Staff Diagnostic...
BioCentury | Jan 4, 2010
Finance

IPO performance

...12/10/09 $4.8 $23.9 $46.7 95% China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) 12/9/09 $40.7 $177.1 $154.6 -13% T-Ray Science Inc....
BioCentury | Dec 14, 2009
Financial News

T-Ray Science completes IPO

T-Ray Science Inc. (TSX-V:THZ), Vancouver, B.C. Business: Diagnostic Date completed: 12/9/09 Type: IPO Raised: C$1.5 million (US$1.4 million) Shares: 7.5 million Price: C$0.20 Shares after offering: 33.1 million Underwriter: Research Capital Corp. Note: Research Capital,...
Items per page:
1 - 7 of 7
BioCentury | Apr 21, 2014
Politics, Policy & Law

ASCO's honest broker

A new access program and registry developed by the American Society of Clinical Oncology to facilitate use of off-label cancer drugs could serve as a model for independent bodies that could manage early access to...
BioCentury | Nov 22, 2010
Company News

T-Ray Science, BC Cancer Agency deal

...an additional 200,000 five-year warrants exercisable at C$0.18 to the agency (see BioCentury, July 19). T-Ray Science Inc....
BioCentury | Jul 26, 2010
Financial News

T-Ray Science proposes private placement of units

T-Ray Science Inc. (TSX-V:THZ), Vancouver, B.C. Business: Diagnostic Date announced: 7/14/10 Type: Private placement of units To be raised: Up to C$660,000 (US$628,188) Units: 3 million Price: C$0.22 (unit) Shares outstanding prior: 33.1 million Note:...
BioCentury | Jul 19, 2010
Company News

T-Ray Science, BC Cancer Agency deal

...warrant exercisable at $0.25, T-Ray's closing price on July 13, the day the deal closed. T-Ray Science Inc....
BioCentury | Jan 25, 2010
Company News

T-Ray Science management update

T-Ray Science Inc. (TSX-V:THZ), Vancouver, B.C. Business: Diagnostic Hired: Tom Walker as SVP of business development, formerly president and CEO of Rapid Laboratory Microsystems Inc. WIR Staff Diagnostic...
BioCentury | Jan 4, 2010
Finance

IPO performance

...12/10/09 $4.8 $23.9 $46.7 95% China Nuokang Bio-Pharmaceutical Inc. (NASDAQ:NKBP) 12/9/09 $40.7 $177.1 $154.6 -13% T-Ray Science Inc....
BioCentury | Dec 14, 2009
Financial News

T-Ray Science completes IPO

T-Ray Science Inc. (TSX-V:THZ), Vancouver, B.C. Business: Diagnostic Date completed: 12/9/09 Type: IPO Raised: C$1.5 million (US$1.4 million) Shares: 7.5 million Price: C$0.20 Shares after offering: 33.1 million Underwriter: Research Capital Corp. Note: Research Capital,...
Items per page:
1 - 7 of 7